340 related articles for article (PubMed ID: 26473667)
21. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
[TBL] [Abstract][Full Text] [Related]
22. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Nam HC; Lee HL; Yang H; Song MJ
Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
[TBL] [Abstract][Full Text] [Related]
24. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
Tatum H; Thuluvath PJ; Lawitz E; Martorell C; DeMicco M; Cohen S; Rustgi V; Ravendhran N; Ghalib R; Hanson J; Zamparo J; Zhao J; Cooney E; Treitel M; Hughes E
J Viral Hepat; 2015 Aug; 22(8):658-64. PubMed ID: 25496007
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
[TBL] [Abstract][Full Text] [Related]
26. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L; Zhang M; Xu M; Chuang WL; Lu W; Xie W; Jia Z; Gong G; Li Y; Bae SH; Yang YF; Xie Q; Lin S; Chen X; Niu J; Jia J; Garimella T; Torbeyns A; McPhee F; Treitel M; Yin PD; Mo L
J Gastroenterol Hepatol; 2016 Nov; 31(11):1860-1867. PubMed ID: 27003037
[TBL] [Abstract][Full Text] [Related]
27. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
[TBL] [Abstract][Full Text] [Related]
29. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
[TBL] [Abstract][Full Text] [Related]
30. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
Hassanein T; Sims KD; Bennett M; Gitlin N; Lawitz E; Nguyen T; Webster L; Younossi Z; Schwartz H; Thuluvath PJ; Zhou H; Rege B; McPhee F; Zhou N; Wind-Rotolo M; Chung E; Griffies A; Grasela DM; Gardiner DF
J Hepatol; 2015 May; 62(5):1204-6. PubMed ID: 25559328
[No Abstract] [Full Text] [Related]
32. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
[TBL] [Abstract][Full Text] [Related]
33. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
Zeuzem S; Hézode C; Bronowicki JP; Loustaud-Ratti V; Gea F; Buti M; Olveira A; Banyai T; Al-Assi MT; Petersen J; Thabut D; Gadano A; Pruitt R; Makara M; Bourlière M; Pol S; Beumont-Mauviel M; Ouwerkerk-Mahadevan S; Picchio G; Bifano M; McPhee F; Boparai N; Cheung K; Hughes EA; Noviello S;
J Hepatol; 2016 Feb; 64(2):292-300. PubMed ID: 26453968
[TBL] [Abstract][Full Text] [Related]
34. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
[TBL] [Abstract][Full Text] [Related]
35. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
36. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM
Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
Moreno C; Hezode C; Marcellin P; Bourgeois S; Francque S; Samuel D; Zoulim F; Grange JD; Shukla U; Lenz O; Ouwerkerk-Mahadevan S; Fevery B; Peeters M; Beumont M; Jessner W
J Hepatol; 2015 May; 62(5):1047-55. PubMed ID: 25596313
[TBL] [Abstract][Full Text] [Related]
38. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
39. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Sulkowski MS; Flamm S; Kayali Z; Lawitz EJ; Kwo P; McPhee F; Torbeyns A; Hughes EA; Swenson ES; Yin PD; Linaberry M
Liver Int; 2017 Jun; 37(6):836-842. PubMed ID: 27943563
[TBL] [Abstract][Full Text] [Related]
40. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
